Business · 10/02/2009Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for LETAIRIS Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for LETAIRIS, a human drug product, in response to patent extension applications submitted to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →